BLINATUMOMAB IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: MECHANISM OF ACTION, CLINICAL RELEVANCE, AND EMERGING THERAPEUTIC PERSPECTIVES
Authors:
- Ewa JachimczakEJEwa Jachimczak
- Vanessa GąsiorowskaVGVanessa Gąsiorowska
- Paulina JarugaPJPaulina Jaruga
- Karolina GrodkowskaKGKarolina Grodkowska
- Ewa WojtanowskaEWEwa Wojtanowska
- Julia KozickaJKJulia Kozicka
- Julia PaczynaJPJulia Paczyna
- Marcin MazurMMMarcin Mazur
- Natalia SmyczyńskaNSNatalia Smyczyńska
- Mateusz MichalakMMMateusz Michalak
Open Access
- 16 June 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Abstract
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and despite significant improvements in survival with intensive chemotherapy, relapse and minimal residual disease (MRD) remain major clinical challenges. Blinatumomab is a bispecific T-cell engager (BiTE) antibody targeting CD19-positive B-cell precursor ALL. By simultaneously binding CD3 on T lymphocytes and CD19 on leukemic cells, it enables major histocompatibility complex (MHC)-independent activation of cytotoxic T cells and targeted elimination of malignant cells. Clinical studies have demonstrated that blinatumomab is effective in inducing remission in relapsed or refractory pediatric ALL and in achieving molecular remission in MRD-positive patients. Compared with conventional chemotherapy, it shows improved efficacy and a more favorable toxicity profile, although cytokine release syndrome and neurotoxicity remain clinically relevant adverse events. Blinatumomab is increasingly used as a bridge to hematopoietic stem cell transplantation and is being investigated in combination regimens and earlier treatment settings. However, therapeutic resistance, including CD19 antigen loss and T-cell dysfunction, remains a limitation. Overall, blinatumomab represents a significant advancement in immunotherapy for pediatric ALL, bridging conventional chemotherapy and cellular therapies such as CAR-T.Keywords
This publication has 18 references indexed in Scilit:
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaNature Medicine, 2018
- Chimeric Antigen Receptor TherapyNew England Journal of Medicine, 2018
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2016
- Acute Lymphoblastic Leukemia in ChildrenNew England Journal of Medicine, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Acute lymphoblastic leukaemiaThe Lancet, 2008
- Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMolecular Immunology, 2006